FDA Brief

Warning letters Drugs

FDA warning letter to

Dr. Brite, LLC

High riskIssued Nov 21, 2024Posted Dec 10, 2024Center for Drug Evaluation and Research (CDER)

FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.

What happened

FDA inspected Dr. Brite’s Fullerton, California drug manufacturing facility from April 2 to 5, 2024, and found violations of current good manufacturing practice (CGMP) for finished drugs. FDA found no adequate testing of incoming components, including glycerin for diethylene glycol (DEG) and ethylene glycol (EG), no adequate finished-product release testing, and an inadequate quality unit. FDA also found oral care products to be unapproved new drugs, hand sanitizer sprays and wipes to be misbranded, and the firm not registered or drug-listed with FDA.

What FDA found

  1. The firm did not test each incoming component lot for identity, purity, strength, and quality, and did not test each glycerin lot for DEG/EG contamination.

    21 CFR 211.84(d)(1) and (2)
  2. The firm did not perform adequate finished-product release testing for identity and strength of active ingredients or for objectionable microorganisms.

    21 CFR 211.165(a) and (b)
  3. The quality control unit did not ensure adequate production controls, stability testing, batch records, or employee training.

    21 CFR 211.22; 211.100(a); 211.137(a); 211.188; 211.25(a)
  4. The oral care products are unapproved new drugs and misbranded because hydroxyapatite is not a permitted active ingredient under the OTC anticaries monograph or antigingivitis/antiplaque rule.

    FD&C Act sections 505(a), 301(d), and 502(ee); 21 U.S.C. 355(a), 331(d), 352(ee)
  5. The hand sanitizer sprays and hand wipes are misbranded drugs.

    FD&C Act section 502(c), 21 U.S.C. 352(c)
  6. The firm was not duly registered with FDA and its drug products were not listed with FDA.

    FD&C Act section 510 and 510(j); 21 CFR Part 207

What FDA wants

Provide DEG and EG test results no later than 30 calendar days from the letter date, plus a risk assessment, testing plans, quality unit remediation, and other corrective actions in response to the letter.

Who should pay attention

  • retailers and distributors selling Dr. Brite oral care and hand sanitizer products
  • brands using glycerin in oral drug products
  • companies that rely on supplier certificates of analysis for high-risk components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk